Drugmakers Challenge Trump's International Drug Pricing Models
Major pharmaceutical and biotech companies are urging the Trump administration to withdraw two Medicare pricing proposals that would align U.S. drug prices with international benchmarks, arguing the mandatory models exceed government authority and threaten innovation.